AstraZeneca Collaborates with DeepMatter for Optimization of Compound Synthesis Leveraging AI and Machine Learning
Shots:
- AstraZeneca team up with DeepMatter to utilize its digital technologies enabled with ML and AI to improve the productivity and reproducibility of compound synthesis
- The collaboration leverages DeepMatter's Digital Glassware data collection and structuring technology to be used with AstraZeneca's automated compound synthesis platform
- Digital Glassware enables users to capture and analyze a rich array of information about their chemical reaction- leverage AI and ML to increase the certainty of producing high quality and choice of candidate drug candidates
Click here to read full press release/ article
Ref: DeepMatter | Image: AstraZeneca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com